Health In Tech, Inc. (HIT)

NCM – Real vaqt narxi. Valyuta: USD

1.52

+0.01 (0.66%)

Yopilishda: May 12, 2026, 4:00 PM EDT

30.04.2026

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).

21.04.2026

Health In Tech to Present at the Market Movers Investor Summit

STUART, Fla., April 21, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) (the "Company"), an AI-enabled InsurTech platform company, today announced that it will be participating in the Market Movers Investor Summit on Tuesday, May 5, 2026.

27.03.2026

Health In Tech Announces Closing of $7.0 Million Private Placement

STUART, Fla., March 27, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced the closing of its previously announced private investment in public equity financing (the "PIPE"), resulting in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.

26.03.2026

Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript

25.03.2026

Health In Tech Announces $7.0 Million Private Placement

STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.

25.03.2026

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Full year 2025 Revenues of $33.3 million, up 71% YoY Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

17.03.2026

Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform

STUART, Fla., March 17, 2026 /PRNewswire/ -- Health In Tech, Inc. (the "Company" or "Health In Tech") (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced a strategic collaboration with Ciklum, a global AI-powered experience engineering and software development firm, to enhance the Company's AI-driven InsurTech platform.

Videolar

No Data

There is no data to display

Press-relizlar

30.04.2026

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

27.03.2026

Health In Tech Announces Closing of $7.0 Million Private Placement

25.03.2026

Health In Tech Announces $7.0 Million Private Placement

25.03.2026

Health In Tech, Inc. (HIT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Health In Tech, Inc. (HIT)

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech to Present at the Market Movers Investor Summit

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform

Videolar

No Data

Press-relizlar

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech to Present at the Market Movers Investor Summit

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform

Videolar

No Data

Press-relizlar

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Search stocks

Health In Tech, Inc. (HIT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Health In Tech, Inc. (HIT)

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech to Present at the Market Movers Investor Summit

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform

Videolar

No Data

Press-relizlar

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech to Present at the Market Movers Investor Summit

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results

Health In Tech and Amazon Web Service Advanced Tier Service Partner Ciklum Announce Strategic Collaboration to Accelerate Development of AI-Driven InsurTech Platform

Videolar

No Data

Press-relizlar

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech Announces Closing of $7.0 Million Private Placement

Health In Tech Announces $7.0 Million Private Placement

Health In Tech Announces Fourth Quarter and Full Year 2025 Financial Results